News - AstraZeneca, Pharmaceutical

Filter

Current filters:

AstraZenecaPharmaceutical

Popular Filters

1 to 25 of 302 results

AstraZeneca reveals designs for new global R&D center and HQ in Cambridge, UK

AstraZeneca reveals designs for new global R&D center and HQ in Cambridge, UK

20-07-2014

Anglo-Swedish pharma major AstraZeneca on Friday revealed designs for its planned network of glass-walled…

AstraZenecaManagementPharmaceuticalResearchUK

AstraZeneca in research accord with Max Planck Institute

AstraZeneca in research accord with Max Planck Institute

08-07-2014

Anglo-Swedish pharma major AstraZeneca has entered an agreement with the Max Planck Institute of Molecular…

AstraZenecaCardio-vascularMetabolicsPharmaceuticalResearch

Cancer immunotherapy market set to grow to nearly $9 billion across major markets in 2022

Cancer immunotherapy market set to grow to nearly $9 billion across major markets in 2022

01-07-2014

The cancer immunotherapy market will experience considerable growth through 2022, increasing from $1.1…

AstraZenecaBristol-Myers SquibbEuropeJapanMarkets & MarketingMED14736Merck & ConivolumabOncologypembrolizumabPharmaceuticalResearchRocheUSAYervoy

Negative view from FDA advisory for AstraZeneca’s olaparib

Negative view from FDA advisory for AstraZeneca’s olaparib

26-06-2014

There was disappointment for Anglo-Swedish pharma major AstraZeneca yesterday when a US Food and Drug…

AstraZenecaLynparzaolaparibOncologyPharmaceuticalRegulationUSA

ADDC and AstraZeneca partner to foster novel drug development among academic research community

ADDC and AstraZeneca partner to foster novel drug development among academic research community

17-06-2014

The Academic Drug Discovery Consortium has entered into a collaboration with Anglo-Swedish pharma major…

AstraZenecaPharmaceuticalResearch

Positive US FDA advisory panel view on PAMORAs

Positive US FDA advisory panel view on PAMORAs

13-06-2014

The majority of US Food and Drug Administration Anesthetic and Analgesic Drug Products Advisory Committee…

AstraZenecaGastro-intestinalsMovantiknaloxegolPharmaceuticalRegulationUSA

AstraZeneca inks up to $232 million deal for Synairgen’s SNG001

AstraZeneca inks up to $232 million deal for Synairgen’s SNG001

12-06-2014

Anglo-Swedish pharma major AstraZeneca has signed a global licence accord with Synairgen, an AIM-listed…

AstraZenecaChronic lower respiratory diseasesHealth Medical PharmaLicensingMajorMedicinePharmaceuticalPulmonologyRespiratory and PulmonarySNG001Synairgen

Gustave Roussy and AstraZeneca form joint oncology research alliance

Gustave Roussy and AstraZeneca form joint oncology research alliance

05-06-2014

The France-based Gustave Roussy comprehensive cancer center and Anglo-Swedish drug major AstraZeneca…

AstraZenecaOncologyPharmaceuticalResearch

AstraZeneca showcases much awaited oncology pipeline at ASCO 2014

AstraZeneca showcases much awaited oncology pipeline at ASCO 2014

03-06-2014

Anglo-Swedish drug major AstraZeneca provided an update on the rapid development of its oncology pipeline…

AstraZenecaAZD9291MED14736MedImmuneOncologyPharmaceuticalResearchtremelimumab

AstraZeneca’s Bydureon controls diabetes better than insulin glargine

AstraZeneca’s Bydureon controls diabetes better than insulin glargine

30-05-2014

Anglo-Swedish pharma major AstraZeneca has announced that Bydureon (exenatide once-weekly injection)…

Anti-diabetic drugsAstraZenecaBydureonDiabetesGlucagonPharmaceuticalResearchUK

AstraZeneca safe (for now?) as Pfizer walks away from pursuit of the firm

26-05-2014

US pharma giant Pfizer, which has been involved in a controversial pursuit of UK-based AstraZeneca, has…

AstraZenecaMergers & AcquisitionsPfizerPharmaceutical

AstraZeneca rejects Pfizer’s improved and “final” offer of £55 a share

AstraZeneca rejects Pfizer’s improved and “final” offer of £55 a share

19-05-2014

After what must have been a hectic weekend of cross Atlantic activity, the board of Anglo-Swedish drug…

AstraZenecaMergers & AcquisitionsPfizerPharmaceutical

Negative IQWiG view on AstraZeneca’s combo diabetes drug Xigduo

16-05-2014

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

AstraZenecaDiabetesGermanyPharmaceuticalPricingRegulationXigduo

AstraZeneca stresses confidence in independence, highlighting strong R&D pipeline

15-05-2014

Anglo-Swedish pharma major AstraZeneca, the subject of the controversial takeover attempt by Pfizer,…

AstraZenecaCardio-vascularMergers & AcquisitionsMetabolicsOncologyPharmaceuticalResearchRespiratory and Pulmonary

$25 million milestone for Ardelyx from tenapanor deal with AstraZeneca

15-05-2014

Closely-held US biopharma firm Ardelyx has received a $25 million milestone payment from Anglo-Swedish…

ArdelyxAstraZenecaLicensingNephrology and HepatologyPharmaceuticalResearchtenapanor

Ligand signs dyslipidemia related diseases accord with AstraZeneca unit

14-05-2014

US drugmaker Ligand Pharmaceuticals has entered into a licensing agreement and research collaboration…

AstraZenecaCardio-vascularLicensingLigand PharmaceuticalsOmthera PharmaceuticalsPharmaceuticalResearch

MedImmune and Incyte to collaborate on immunotherapy

MedImmune and Incyte to collaborate on immunotherapy

14-05-2014

MedImmune, the global biologics research and development arm of Anglo-Swedish drug major AstraZeneca,…

AstraZenecaBahija JallalIncyteL1LicensingMajorMedImmuneOncologyPharmaceuticalTumorTumorsUKUSA

AstraZeneca accuses Pfizer of opportunism, as UK investigation kicks off

AstraZeneca accuses Pfizer of opportunism, as UK investigation kicks off

13-05-2014

As the arguments continue over the benefits or otherwise of US pharma giant Pfizer’s £63 billion ($106…

AstraZenecaMergers & AcquisitionsPfizerPharmaceuticalPoliticsUK

Positive top-line results for MedImmune RA and lupus treatments

Positive top-line results for MedImmune RA and lupus treatments

13-05-2014

Anglo-Swedish drug major AstraZeneca has announced that two key molecules in its global biologics R&D…

Anti-Arthritics/RheumaticsAstraZenecaBahija JallalHealthHealth Medical PharmaMajorMedicineMedImmunePharmaceuticalResearchUK

AstraZeneca sets out its value stall, projecting annual revenues of $45 billion by 2023

AstraZeneca sets out its value stall, projecting annual revenues of $45 billion by 2023

06-05-2014

In a bid to explain its rejection of US pharma giant Pfizer’s increased takeover bid for the Anglo-Swedish…

AstraZenecaFinancialMergers & AcquisitionsPfizerPharmaceuticalResearch

US FDA approval for AstraZeneca’s Epanova

US FDA approval for AstraZeneca’s Epanova

06-05-2014

There was good news today for Anglo-Swedish drug major AstraZeneca, as the US Food and Drug Administration…

AstraZenecaCardio-vascularEpanovaLovazaPharmaceuticalRegulationUSAVascepa

Pfizer’s 4th-qtr 2014 profits and sales slump on generic competition

Pfizer’s 4th-qtr 2014 profits and sales slump on generic competition

06-05-2014

US pharma giant Pfizer, which is aggressively pursuing a takeover of Anglo-Swedish drug major AstraZeneca,…

AstraZenecaFinancialMergers & AcquisitionsPfizerPharmaceutical

AstraZeneca board rejects Pfizer’s increased offer

AstraZeneca board rejects Pfizer’s increased offer

02-05-2014

Within just a few hours of US pharma giant Pfizer announcing an increased offer price for Anglo-Swedish…

AstraZenecaMergers & AcquisitionsPfizerPharmaceutical

Pfizer sweetens takeover offer for AstraZeneca to £50 a share

Pfizer sweetens takeover offer for AstraZeneca to £50 a share

02-05-2014

After much speculation and a lightning visit by Pfizer’s chief executive Ian Read to the UK to woo…

AstraZenecaMergers & AcquisitionsPfizerPharmaceutical

1 to 25 of 302 results

Back to top